Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Benefits of GLP1 RA And SGLT-2 Inhibitors in Type 2 Patients
Speech Impediment a Risk for Type 2 Diabetes
MOST POPULAR ARTICLES OF THE MONTH
#1 The Preferred Insulin for the Elderly
Letter from the Editor
Laura Martínez López, PharmD. Candidate 2021, LECOM, College of Pharmacy, presented us with a feature that looks at the benefits of GLP-1 agonists and SGLT-2 inhibitors in decreasing coronary health disease in patients with type 2 diabetes. The results with either product were very positive. So how do you make a choice? A1c and weight may be a deciding factor, as will the use of insulin. However, there may be one good reason to chose SGLT-2 inhibitors, and that could be the effect these drugs have on patients with chronic kidney disease.
Check out Laura’s Laterpay article and the newsflash from our publisher Steve Freed.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: FDA Approves Dapagliflozin for Chronic Kidney Disease
The FDA has approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) at risk for disease progression. This new approval in chronic kidney disease was based on results of the DAPA-CKD trial that was stopped early in March 2020 due to the efficacy of the treatment.
TOP STORIES — Diabetes News and Research
GLP1 RA and SGLT-2 were compared to evaluate coronary health disease reduction in patients with type 2 diabetes.
A new study shows that teenage boys who stutter may have a higher likelihood of developing early-onset type 2 diabetes.
Personalized medicine may provide a better way of determining the ideal range for sodium consumption.